Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.